|
PRTA | Prothena Corp Public Ltd Co |
|
|
PRTA | Prothena Corp Public Ltd Co |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.59 |
| Leverage | 5.18% |
| Market Cap | $ 485.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -43.8m |
| Margin | -80.03% |
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.